We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

288 hedge funds and large institutions have $5.34B invested in Intra-Cellular Therapies Inc. in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 115 increasing their positions, 78 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more call options, than puts

Call options by funds: $16.6M | Put options by funds: $10.7M

47% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 78

42% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 36

38% more funds holding in top 10

Funds holding in top 10: 8 → 11 (+3)

18% more capital invested

Capital invested by funds: $4.55B → $5.34B (+$797M)

5% more funds holding

Funds holding: 274 → 288 (+14)

Holders
288
Holders Change
+14
Holders Change %
+5.11%
% of All Funds
4.52%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.17%
New
51
Increased
115
Reduced
78
Closed
36
Calls
$16.6M
Puts
$10.7M
Net Calls
+$5.94M
Net Calls Change
-$34M

Top Buyers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.7M
2
Holocene Advisors
Holocene Advisors
New York
+$36.1M
3
Macquarie Group
Macquarie Group
Australia
+$35.4M
4
NIP
Nicholas Investment Partners
California
+$31.1M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$30.5M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$207M
2
WA
Wasatch Advisors
Utah
-$62M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$47.1M
4
DM
Deerfield Management
New York
-$39.7M
5
Citadel Advisors
Citadel Advisors
Florida
-$36.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
HSBC Holdings
226
HSBC Holdings
United Kingdom
$232K +$228K +3,659 New
MML Investors Services
227
MML Investors Services
Massachusetts
$231K -$69.6K -1,117 -23%
Janney Montgomery Scott
228
Janney Montgomery Scott
Pennsylvania
$229K +$226K +3,621 New
Canada Life
229
Canada Life
Manitoba, Canada
$225K -$46.9K -752 -18%
SAM
230
Shikiar Asset Management
New York
$222K +$218K +3,500 New
VPIM
231
Vanguard Personalized Indexing Management
California
$221K +$218K +3,491 New
PI
232
PFS Investments
Georgia
$221K +$217K +3,490 New
RJT
233
Raymond James Trust
Florida
$206K +$202K +3,248 New
TRCT
234
Tower Research Capital (TRC)
New York
$170K +$35.1K +563 +27%
EIM
235
Essex Investment Management
Massachusetts
$135K – – –
HT
236
Headlands Technologies
Illinois
$129K +$127K +2,045 New
AssetMark Inc
237
AssetMark Inc
California
$114K +$64.5K +1,035 +136%
US Bancorp
238
US Bancorp
Minnesota
$111K +$6.54K +105 +6%
CSPIA
239
Cary Street Partners Investment Advisory
Virginia
$101K – – –
GRP
240
Global Retirement Partners
California
$97.5K – – –
C
241
Covestor
United Kingdom
$97K -$56.5K -906 -37%
CUAMC
242
China Universal Asset Management Company
China
$79.7K -$1.56K -25 -2%
BCM
243
Blume Capital Management
California
$79.2K – – –
PA
244
Parallel Advisors
California
$78K – – –
GWSG
245
GPS Wealth Strategies Group
Colorado
$63.3K – – –
KTC
246
Kistler-Tiffany Companies
Pennsylvania
$63.3K – – –
SOW
247
State of Wyoming
Wyoming
$53.9K +$19.4K +312 +58%
HCA
248
Harbor Capital Advisors
Illinois
$46.5K +$45.7K +734 New
AF
249
Allworth Financial
California
$42.2K +$21.2K +340 +104%
HNB
250
Huntington National Bank
Ohio
$42K +$13.5K +217 +49%
8 9
10
11 12

ITCI Hedge Fund Activity: Q2 2023 in Review

288 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2023, worth a combined $5.34B — up 18% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new ITCI positions and 36 closed out — a net gain of 15 holders — while 115 added to existing stakes and 78 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $36.7M. The largest seller was Wellington Management Group, cutting an estimated $207M.

  • 288 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2023, up from 274 in Q1 2023.
  • Funds reported $5.34B of Intra-Cellular Therapies Inc. stock for Q2 2023, up 18% quarter-over-quarter.
  • 51 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2023 and 36 closed out, a net change of +15 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2023 was Lord, Abbett & Co, an estimated $36.7M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2023 was Wellington Management Group, an estimated $207M sold.

Based on aggregated 13F filings for Q2 2023.